Fewer side-effects and similar benefits from shorter chemotherapy after bowel cancer surgery
This expert commentary is provided for an RCT which found a similar three year progression free survival for 3 months and 6 months of chemotherapy. Most guidelines recommend six months treatment, this study gives the potential to improve acceptability and uptake of treatment
LAST Monday, I sat in a chair in a medical day unit while chemotherapy medication went into my vein. A drug called oxaliplatin which, with daily tablets of capecitabine to follow, are my ongoing treatment for bowel cancer.
Many patients receiving chemotherapy following surgery for bowel cancer may only need three months treatment rather than the six months currently given, according to researchers.
Blood test for carcinoembryonic antigen could help determine whether to use chemotherapy Related items fromOnMedica Aspirin linked to better colon cancer survival Developing and using a tool to improve outcomes in colorectal cancer Fifth of emergency bowel cancer cases had red flag symptoms Long delay after FIT linked to higher risk of cancer
COLON cancer - also known as bowel cancer - survival has doubled in the last 40 years in the UK, but there are still thousands of deaths from the condition each year.
Last year, Robert Holt from London was diagnosed with bowel cancer for the second time, but his body was no longer responding to treatments. He became one of the first to try the new 'chemotherapy bath'.
Authors: Abstract My husband Richard - known to everyone as Jake - had been admitted to ward 21 at the Royal Shrewsbury Hospital in Shropshire with side effects from stage five small bowel cancer. We knew his diagnosis was terminal, but at this point we thought he still had 18-24 months to live, following seven cycles of chemotherapy. PMID: 28198334 [PubMed - in process]
This study has immediate clinical relevance for health care professionals in oncology, palliative care and primary care.
ConclusionsThis review suggests that in patients with solid tumours, where there is a relationship between chemotherapy treatment and cognitive impairment, the type and level of cognitive decline does not consistently appear to have an impact on such patients’ HRQoL. This could be partly explained by variations in study design, measures used, definitions of cognitive impairment, varying measurement time frames, small sample sizes and differences in disease severity and type of treatment regimes.
Mother-of-two Jodi Huggett, 41, from Caistor, near Grimsby, underwent four rounds of chemo after an operation to remove a low-grade form of bowel cancer but didn't need that type of treatment.
(NaturalNews) The U.S. government's policy on cancer is far from perfect. When it comes to this deadly disease, the strategy proposed is simple: chemotherapy, surgery and radiation. Just in the U.S.A, cancer takes the lives of almost 600,000 people every year, making it a significant...